Balancing antiviral potency and host toxicity: Identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase

Molecular Pharmacology

Volumn 82, Issue 1, 2012, Pages 125-133

  Sohl, Christal D ^a   Kasiviswanathan, Rajesh ^b   Kim, Jiae ^a   Pradere, Ugo ^c,d   Schinazi, Raymond F ^c,d   Copeland, William C ^b   Mitsuya, Hiroaki ^e,f   Baba, Masanori ^g   Anderson, Karen S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e KUMAMOTO UNIVERSITY   (Japan)

^f NATIONAL CANCER INSTITUTE   (United States)

^g KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 3 DEOXY 4 ETHYNYLTHYMIDINE; 3' FLUOROTHYMIDINE; DNA DIRECTED DNA POLYMERASE GAMMA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRIAL TOXICITY; PHENOTYPE; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DNA, MITOCHONDRIAL; DNA-DIRECTED DNA POLYMERASE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE;

EID: 84862529537     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.078758     Document Type: Article

References (54)

1. Apostolova N, Blas-García A, and Esplugues JV (2011) Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. Trends Pharmacol Sci 32: 715-725.
2. Bailey CM, Kasiviswanathan R, Copeland WC, and Anderson KS (2009) R964C mutation of DNA polymerase gamma imparts increased stavudine toxicity by decreasing nucleoside analog discrimination and impairing polymerase activity. Antimicrob Agents Chemother 53:2610-2612.
3. Bienstock RJ and Copeland WC (2004) Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase. Mitochondrion 4:203-213. (Pubitemid 39549810)
4. Brinkman K, Smeitink JA, Romijn JA, and Reiss P (1999) Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354:1112-1115. (Pubitemid 29452832)
5. Cheng YC, Dutschman GE, Bastow KF, Sarngadharan MG, and Ting RY (1987) Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem 262:2187-2189. (Pubitemid 17102656)
6. de Baar MP, de Rooij ER, Smolders KG, van Schijndel HB, Timmermans EC, and Bethell R (2007) Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells. Antiviral Res 76:68-74. (Pubitemid 47176695)
7. De Clercq E (2010) Antiretroviral drugs. Curr Opin Pharmacol 10:507-515.
8. Dutschman GE, Grill SP, Gullen EA, Haraguchi K, Takeda S, Tanaka H, Baba M, and Cheng YC (2004) Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother 48:1640-1646. (Pubitemid 38544369)
9. Feng JY and Anderson KS (1999) Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry 38:55-63. (Pubitemid 29035670)
10. Feng JY, Johnson AA, Johnson KA, and Anderson KS (2001) Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 276:23832-23837.
11. Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, Schinazi RF, Furman PA, and Anderson KS (2004) Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother 48:1300-1306. (Pubitemid 38405485)
12. Flexner C, van der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, Barditch-Crovo PA, Petty BG, Baron PA, and Armstrong D (1994) Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 170: 1394-1403.
13. Graziewicz MA, Longley MJ, Bienstock RJ, Zeviani M, and Copeland WC (2004) Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nat Struct Mol Biol 11:770-776. (Pubitemid 39014503)
14. Hanes JW and Johnson KA (2008) Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase. Antimicrob Agents Chemother 52:253-258.
15. Haraguchi K, Takeda S, Tanaka H, Nitanda T, Baba M, Dutschman GE, and Cheng YC (2003) Synthesis of a highly active new anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine. Bioorg Med Chem Lett 13:3775-3777. (Pubitemid 37206505)
16. Johnson AA and Johnson KA (2001) Exonuclease proofreading by human mitochondrial DNA polymerase. J Biol Chem 276:38097-38107.
17. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, and Johnson KA (2001) Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 276:40847-40857. (Pubitemid 37373231)
18. Johnson AA, Tsai Y, Graves SW, and Johnson KA (2000) Human mitochondrial DNA polymerase holoenzyme: reconstitution and characterization. Biochemistry 39:1702-1708. (Pubitemid 30108960)
19. Kasiviswanathan R, Longley MJ, Young MJ, and Copeland WC (2010) Purification and functional characterization of human mitochondrial DNA polymerase gamma harboring disease mutations. Methods 51:379-384.
20. Kerr SG and Anderson KS (1997) RNA dependent DNA replication fidelity of HIV-1 reverse transcriptase: evidence of discrimination between DNA and RNA substrates. Biochemistry 36:14056-14063. (Pubitemid 27509840)
21. Kim EY, Vrang L, Oberg B, and Merigan TC (2001) Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants. AIDS Res Hum Retroviruses 17:401-407. (Pubitemid 32506931)
22. Kim J, Roberts A, Yuan H, Xiong Y, and Anderson KS (2012) Nucleocapsid protein annealing of a primer-template enhances (+)-strand DNA synthesis and fidelity by HIV-1 reverse transcriptase. J Mol Biol 415:866-880.
23. Kirby KA, Singh K, Michailidis E, Marchand B, Kodama EN, Ashida N, Mitsuya H, Parniak MA, and Sarafianos SG (2011) The sugar ring conformation of 4′-ethynyl-2-fluoro-2′-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase. Cell Mol Biol (Noisy-le-grand) 57:40-46.
24. Koczor CA and Lewis W (2010) Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA. Expert Opin Drug Metab Toxicol 6:1493-1504.
25. Kohler JJ and Lewis W (2007) A brief overview of mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen 48:166-172. (Pubitemid 46536084)
26. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, Ostrander M, Lang SA Jr, Muchmore E, and Chou TC (1992) Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 36:808-818.
27. Lee H, Hanes J, and Johnson KA (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711-14719. (Pubitemid 37553499)
28. Lee YS, Kennedy WD, and Yin YW (2009) Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations. Cell 139:312-324.
29. Lim SE, Ponamarev MV, Longley MJ, and Copeland WC (2003) Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. J Mol Biol 329:45-57. (Pubitemid 36555165)
30. Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, Revie DR, Khan NC, Federici ME, and Li H (1994) Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 170:1157-1164. (Pubitemid 24328618)
31. Longley MJ, Ropp PA, Lim SE, and Copeland WC (1998) Characterization of the native and recombinant catalytic subunit of human DNA polymerase gamma: identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry 37:10529-10539. (Pubitemid 28357578)
32. Michailidis E, Marchand B, Kodama EN, Singh K, Matsuoka M, Kirby KA, Ryan EM, Sawani AM, Nagy E, Ashida N, et al. (2009) Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem284:35681-35691.
33. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, and Broder S (1985) 3′-Azido-3′- deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitro. Proc Natl Acad Sci USA 82:7096-7100. (Pubitemid 16209699)
34. Murakami E, Basavapathruni A, Bradley WD, and Anderson KS (2005) Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases. Antiviral Res 67:10-17. (Pubitemid 40798913)
35. Murakami E, Feng JY, Lee H, Hanes J, Johnson KA, and Anderson KS (2003) Characterization of novel reverse transcriptase and other RNA-associated catalytic activities by human DNA polymerase gamma: importance in mitochondrial DNA replication. J Biol Chem 278:36403-36409. (Pubitemid 37139969)
36. Nitanda T, Wang X, Kumamoto H, Haraguchi K, Tanaka H, Cheng YC, and Baba M (2005) Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob Agents Chemother 49:3355-3360. (Pubitemid 41060582)
37. Paintsil E, Dutschman GE, Hu R, Grill SP, Lam W, Baba M, Tanaka H, and Cheng YC (2007) Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2′,3′-didehydro-3′-deoxy- 4′-ethynylthymidine, a novel thymidine analog. Antimicrob Agents Chemother 51:3870-3879. (Pubitemid 350057783)
38. Ray AS, Basavapathruni A, and Anderson KS (2002a) Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem 277:40479-40490. (Pubitemid 35215625)
39. Ray AS, Murakami E, Peterson CN, Shi J, Schinazi RF, and Anderson KS (2002b) Interactions of enantiomers of 2′,3′-didehydro-2′, 3′-dideoxy-fluorocytidine with wild type and M184V mutant HIV-1 reverse transcriptase. Antiviral Res 56:189-205. (Pubitemid 35284294)
40. Ray AS, Schinazi RF, Murakami E, Basavapathruni A, Shi J, Zorca SM, Chu CK, and Anderson KS (2003) Probing the mechanistic consequences of 5-fluorine substitution on cytidine nucleotide analogue incorporation by HIV-1 reverse transcriptase. Antivir Chem Chemother 14:115-125. (Pubitemid 37087251)
41. Ray AS, Yang Z, Shi J, Hobbs A, Schinazi RF, Chu CK, and Anderson KS (2002c) Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry 41:5150-5162. (Pubitemid 34411669)
42. Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, and Anderson KS (2012) Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine indicates a low potential for host toxicity. Antimicrob Agents Chemother 56:1630-1634.
43. Song S, Pursell ZF, Copeland WC, Longley MJ, Kunkel TA, and Mathews CK (2005) DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci USA 102:4990-4995.
44. Tanaka H, Haraguchi K, Kumamoto H, Baba M, and Cheng YC (2005) 4′-Ethynylstavudine (4′-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants. Antivir Chem Chemother 16:217-221. (Pubitemid 41139708)
45. Vaccaro JA and Anderson KS (1998) Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3′-azido-3′-deoxythymidine (AZT) resistance. Biochemistry 37:14189-14194. (Pubitemid 28471254)
46. Vaccaro JA, Parnell KM, Terezakis SA, and Anderson KS (2000) Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: an equivalent incorporation efficiency relative to the natural substrate dTTP. Antimicrob Agents Chemother 44:217-221. (Pubitemid 30010704)
47. Venhoff AC, Lebrecht D, Reuss FU, Heckl-Ostreicher B, Wehr R, Walker UA, and Venhoff N (2009) Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug. Antimicrob Agents Chemother 53:2748-2751.
48. Wang L, Sun R, and Eriksson S (2011) The kinetic effects on thymidine kinase 2 by enzyme-bound dTTP may explain the mitochondrial side effects of antiviral thymidine analogs. Antimicrob Agents Chemother 55:2552-2558.
49. Wheeler LJ and Mathews CK (2011) Nucleoside triphosphate pool asymmetry in mammalian mitochondria. J Biol Chem 286:16992-16996.
50. Wiń ska P, Miazga A, Poznań ski J, and Kulikowski T (2010) Partial selective inhibition of HIV-1 reverse transcriptase and human DNA polymerases γ and β by thiated 3′-fluorothymidine analogue 5′-triphosphates. Antiviral Res 88:176-181.
51. Yamanaka H, Gatanaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, Kimura S, and Oka S (2007) Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 195:1419-1425. (Pubitemid 46717459)
52. Yang G, Dutschman GE, Wang CJ, Tanaka H, Baba M, Anderson KS, and Cheng YC (2007) Highly selective action of triphosphate metabolite of 4′-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res 73:185-191.
53. Yang G, Paintsil E, Dutschman GE, Grill SP, Wang CJ, Wang J, Tanaka H, Hamasaki T, Baba M, and Cheng YC (2009) Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4′-ethynylthymidine analog resistance profile. Antimicrob Agents Chemother 53: 4640-4646.
54. Yang G, Wang J, Cheng Y, Dutschman GE, Tanaka H, Baba M, and Cheng YC (2008) Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4′-ethynyl stavudine triphosphate. Antimicrob Agents Chemother 52:2035-2042. (Pubitemid 351758540)